Company Overview and News

 
Michael Hill International names Daniel Bracken as new CEO

7h nzherald.co.nz
Michael Hill International has named the head of Specialty Fashion Group as its new chief executive.
MHI MXRHY SFH MXRHF

 
Michael Hill International Ltd. ADR 2018 Q4 - Results - Earnings Call Slides

2018-08-27 seekingalpha
The following slide deck was published by Michael Hill International Ltd. ADR in conjunction with their 2018 Q4 earnings call.
MHI MXRHY MXRHF

 
NZ shares hit record; Synlait, a2 gain while Sky TV, Z Energy drop

2018-08-27 nzherald.co.nz
New Zealand shares hit a record, led higher by Synlait Milk and a2 Milk Co while Sky Network Television continued Friday's decline.
MQBKY AIA MHI ZNRGF MXRHY MCQEF ACKDF ZEL AUKNY SKT ZNZ SYKWF AIA SKKTY SKLUY SKL MQG SML MXRHF

 
Michael Hill profit sinks 86 per cent on US exit

2018-08-26 nzherald.co.nz
Michael Hill International's full-year profit tumbled 86 per cent on Emma & Roe and US closure costs but the retailer says its new strategy has it positioned for growth.
MHI MXRHY MXRHF

1
Michael Hill lifts full-year revenue as it shifts focus back to core namesake brand

2018-07-10 nzherald.co.nz - 1
Michael Hill International increased revenue 3.3 per cent in its 2018 fiscal year as it opened more namesake brand stores in Australia and Canada, exited its US operations and began the closure of its Emma & Roe chain.
MHI MXRHY MXRHF

11
Shares rise after bumpy week, led by NZ Refining

2018-06-22 nzherald.co.nz
New Zealand shares rose, led by New Zealand Refining Company and Synlait Milk while Port of Tauranga and A2 Milk Co fell.
PPL FBU PUPKY MHI FCREY MXRHY NZR FRCEF SKT SYKWF PPSHY FBU SKKTY SML MXRHF

 
Michael Hill Jeweller pulls plug on low-cost brand

2018-06-22 radionz.co.nz
Jewellery retailer Michael Hill International will close its remaining Emma and Roe shops and concentrate on its core brand.
MHI MXRHY MXRHF

 
Michael Hill to close last Emma & Roe stores

2018-06-21 nzherald.co.nz
Michael Hill International said it plans to close the remaining six stores of its Emma & Roe chain as well as the sub-brand's online business.
MHI MXRHY MXRHF

11
A2 to join MSCI main stock index as Mercury drops off

2018-05-14 nzherald.co.nz
A review of global stock indices by MSCI will, as expected, add A2 Milk to the international investment advisor's main global index, with Mercury New Zealand to be removed.
BGR FBU MHI FBU THL FCREY MXRHY FRCEF MXRHF SML

11
Fletcher gains as stock stays in MSCI main index

2018-05-14 nzherald.co.nz
A review of global stock indices by MSCI has seen Fletcher Building shares gain after news the stock will remain on the international investment adviser's main global index, with A2 Milk rising on its planned entry and Mercury New Zealand dipping due to its planned removal.
BGR FBU MHI FBU THL FCREY MXRHY FRCEF MXRHF SML

1
Exit from US jewellery business to cost Michael Hill $6m

2018-04-11 nzherald.co.nz - 1
Michael Hill International said the exit from its US business is expected to cost US$4.5 million (NZ$6.1 million) for lease terminations and employee severance costs after it was unable to find a buyer for the jewellery stores.
MHI MXRHY MXRHF

Related Articles

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...

EKSO: Ekso Bionics Holdings Analysis and Research Report

2018-09-18 - Asif

Overview The company design, develop and sell exoskeleton technology to augment human strength, endurance and mobility. The company's exoskeleton technology serves multiple markets and can be used both by able-bodied users as well as by persons with physical disabilities. Ekso Bionics has sold, rented or leased devices that (a) enable individuals with neurological conditions affecting gait (stroke and spinal cord injury) to rehabilitate and to walk again and (b) allow industrial workers to perform heavy duty work for extended periods. Today, its medical exoskeleton, Ekso GT, is used as a rehabilitation tool to allow physicians and therapists to rehabilitate patients who have suffered a stroke or spinal cord injury. With its unique features designed specifically for hospitals and its proprietary SmartAssist software, Ekso GT allows for the early mobilization of patients, with high step count and high dosage treatments. The intent is to allow the patient’s central nervous syst...

AGRX: Agile Therapeutics Analysis and Research Report

2018-09-18 - Asif

Overview Agile Therapeutics is a forward-thinking women’s healthcare company dedicated to fulfilling the unmet health needs of today’s women. Twirla® and its other current potential product candidates are designed to provide women with contraceptive options that offer greater convenience and facilitate compliance. The company's lead product candidate, Twirla, also known as AG200-15, is a once-weekly prescription contraceptive patch that is at the end of Phase 3 clinical development. Since its inception in 1997, Agile Therapeutics has devoted substantial resources to developing Twirla, building its intellectual property portfolio, business planning, raising capital and providing general and administrative support for these operations. The company incurred research and development expenses of $14.4 million, $20.9 million and $25.6 million during the years ended December 31, 2017, 2016 and 2015, respectively. The company incurred research and development expenses of $2.4 milli...